Elite Pharmaceuticals Inc (ELTP) financial statements (2021 and earlier)
Company profile
| Business Address |
165 LUDLOW AVENUE NORTHVALE, NJ 07647 |
| State of Incorp. | NV |
| Fiscal Year End | March 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 Q3 | 9/30/2020 Q2 | 6/30/2020 Q1 | 3/31/2020 Q4 | 12/31/2019 Q3 | 9/30/2019 Q2 | 6/30/2019 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5 | 4 | 3 | 1 | 2 | 2 | 3 | ||
| Cash and cash equivalents | 5 | 4 | 3 | 1 | 2 | 2 | 3 | ||
| Receivables | 3 | 4 | 4 | 4 | 3 | 2 | 1 | ||
| Inventory, net of allowances, customer advances and progress billings | 5 | 4 | 6 | 4 | 4 | 4 | 5 | ||
| Inventory | 5 | 4 | 6 | 4 | 4 | 4 | 5 | ||
| Other undisclosed current assets | 1 | 0 | 1 | 1 | 1 | 0 | 0 | ||
| Total current assets: | 15 | 13 | 13 | 10 | 9 | 8 | 9 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Property, plant and equipment | 7 | 7 | 7 | 7 | 8 | 8 | 8 | ||
| Intangible assets, net (including goodwill) | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||
| Intangible assets, net (excluding goodwill) | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||
| Other noncurrent assets | 0 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 14 | 14 | 15 | 15 | 15 | 15 | 16 | ||
| TOTAL ASSETS: | 29 | 28 | 28 | 25 | 24 | 24 | 24 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5 | 5 | 7 | 6 | 5 | 6 | 6 | ||
| Accounts payable | 1 | 1 | 2 | 2 | 1 | 2 | 2 | ||
| Accrued liabilities | 5 | 5 | 5 | 5 | 4 | 4 | 4 | ||
| Deferred revenue | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||
| Debt | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||
| Due to related parties | 1 | ||||||||
| Other undisclosed current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Total current liabilities: | 7 | 7 | 9 | 9 | 8 | 7 | 8 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 3 | 3 | 3 | 2 | 2 | 2 | 2 | ||
| Long-term debt, excluding current maturities | 3 | 3 | 3 | 2 | 2 | 2 | 2 | ||
| Operating lease, liability | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Liabilities, other than long-term debt | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||
| Deferred revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Due to related parties | 1 | 1 | |||||||
| Other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent liabilities | 2 | 3 | 4 | 4 | 5 | 2 | 1 | ||
| Total noncurrent liabilities: | 5 | 6 | 7 | 6 | 7 | 6 | 5 | ||
| Total liabilities: | 12 | 13 | 16 | 14 | 15 | 13 | 12 | ||
| Temporary equity, carrying amount | 14 | 14 | |||||||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 17 | 15 | 12 | 11 | 9 | (3) | (2) | ||
| Preferred stock | 14 | 14 | 14 | ||||||
| Common stock | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Treasury stock, value | (0) | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Additional paid in capital | 164 | 164 | 150 | 150 | 150 | 150 | 149 | ||
| Accumulated deficit | (148) | (150) | (153) | (154) | (155) | (153) | (152) | ||
| Total stockholders' equity: | 17 | 15 | 12 | 11 | 9 | (3) | (2) | ||
| TOTAL LIABILITIES AND EQUITY: | 29 | 28 | 28 | 25 | 24 | 24 | 24 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 Q3 | 9/30/2020 Q2 | 6/30/2020 Q1 | 3/31/2020 Q4 | 12/31/2019 Q3 | 9/30/2019 Q2 | 6/30/2019 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 6 | 7 | 8 | 12 | 5 | 5 | 3 | |
| Cost of revenue | (3) | (4) | (5) | (6) | (2) | (3) | (2) | |
| Gross profit: | 3 | 4 | 3 | 6 | 3 | 1 | 1 | |
| Operating expenses | (2) | (2) | (2) | (1) | (2) | (2) | (2) | |
| Operating income (loss): | 1 | 1 | 1 | 5 | 1 | (0) | (1) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 1 | 1 | (1) | 0 | (3) | (1) | 1 | |
| Interest and debt expense | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| Income (loss) from continuing operations before equity method investments, income taxes: | 2 | 2 | 0 | 5 | (2) | (2) | 0 | |
| Other undisclosed income (loss) from continuing operations before income taxes | 0 | 0 | 0 | (0) | 0 | 0 | 0 | |
| Income (loss) from continuing operations before income taxes: | 2 | 2 | 0 | 4 | (2) | (2) | 0 | |
| Income tax benefit | 1 | |||||||
| Income (loss) from continuing operations: | 2 | 2 | 1 | 4 | (2) | (2) | 0 | |
| Loss from discontinued operations | (1) | |||||||
| Income (loss) before gain (loss) on sale of properties: | 2 | 1 | 1 | 4 | (2) | (2) | 0 | |
| Other undisclosed net income (loss) | 1 | (0) | (0) | |||||
| Net income (loss) available to common stockholders, basic: | 2 | 2 | 1 | 4 | (2) | (2) | 0 | |
| Other undisclosed net income (loss) available to common stockholders, diluted | (1) | 2 | (2) | |||||
| Net income (loss) available to common stockholders, diluted: | 2 | 1 | 1 | 6 | (2) | (2) | (1) | |
Comprehensive Income ($ in millions)
| 12/31/2020 Q3 | 9/30/2020 Q2 | 6/30/2020 Q1 | 3/31/2020 Q4 | 12/31/2019 Q3 | 9/30/2019 Q2 | 6/30/2019 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 2 | 2 | 1 | 4 | (2) | (2) | 0 | |
| Comprehensive income (loss), net of tax, attributable to parent: | 2 | 2 | 1 | 4 | (2) | (2) | 0 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.